Psychedelic-Assisted Psychotherapy as a Tool on the Tool Belt to Address Population Mental Health

Type:
  Training
Duration:
1 hour
CE credits:
1.0 CEs
Presented by:
DMH + UCLA Prevention Center of Excellence
Featuring:
Alex Kelman, PhD and Jessica Jeffrey, MD, MBA, MPH
Series:
Stress, Trauma, and Resilience (STAR) Seminars
Relevant categories:
Behavioral Health
  Access requires that you create an account or login.

Overview

In this Stress, Trauma, and Resilience (STAR) Seminar, Dr. Alex Kelman and Dr. Jessica Jeffrey will explain and present a high level primer on psychedelic-assisted psychotherapy (PAP). Dr. Kelman and Dr. Jeffrey will be discussing the current legal pathways for patients to engage in PAP. Additionally, this training will be offering a future perspective regarding what PAPs may be available in the upcoming years and describe specific trials currently enrolling participants. Finally, Dr. Kelman and Dr. Jeffrey will be delineating the specific clinical indications with the largest evidence base for PAP, as well as future directions to be explored by the broader research community.

  Public link for sharing: https://learn.wellbeing4la.org/detail?id=401006&k=47756311  
Copied!

Learning objectives

  • Describe the state of the science on psychedelic medicine as a mental health treatment
  • Explain the currently available, legal mechanisms to engage in psychedelic assisted psychotherapy
  • List which clinical indications psychedelic assisted psychotherapy has the strongest evidence base for

Professional credit

  • This activity offers the following types of credit: APA
  • 1.0 CEs are available.
  • Additional details can be found in the activity document for this resource.

Attachments

  This resource has attachments. To view them, login or sign up.

Related items

SITREP: New Directions in Treatment for Veterans With Psychedelic-Assisted Therapy

Current evidence-based psychotherapies often provide less than satisfactory results for veterans struggling with the so-called "hidden wounds of war" (e.g., PTSD, anxiety, and depression). After 20 years of continuous warfare, veterans require and demand new and effective modalities. Fortunately, important new treatments are emerging on the horizon. The FDA granted breakthrough status for treatments with psilocybin and MDMA, and veterans are the likely recipients of these emerging therapeutic practices that psychedelic-assisted therapies (PAT) typify. The clinical uses, research outcomes, and rationales for the FDA's granting ...

 Training
  1 hour, 29 minutes
  Added on 2/11/2023
Added on 11/30/2022